Jump Financial LLC Makes New $81,000 Investment in OPKO Health, Inc. $OPK

Jump Financial LLC purchased a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 49,070 shares of the biotechnology company’s stock, valued at approximately $81,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in OPK. Oak Thistle LLC bought a new position in OPKO Health during the first quarter worth about $26,000. GM Advisory Group LLC bought a new position in OPKO Health during the first quarter worth about $33,000. Cerity Partners LLC bought a new position in OPKO Health during the first quarter worth about $36,000. Wealth Enhancement Advisory Services LLC lifted its stake in OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,417 shares during the period. Finally, Pallas Capital Advisors LLC bought a new position in OPKO Health during the first quarter worth about $43,000. Institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

OPK has been the subject of a number of research analyst reports. Zacks Research upgraded shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. LADENBURG THALM/SH SH raised OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $2.75.

OPKO Health Stock Performance

OPK stock opened at $1.35 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The company has a 50 day moving average price of $1.35 and a 200 day moving average price of $1.44. OPKO Health, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The stock has a market capitalization of $1.07 billion, a PE ratio of -5.40 and a beta of 1.40.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.The company had revenue of $156.80 million during the quarter, compared to the consensus estimate of $165.74 million. During the same quarter last year, the firm earned ($0.01) EPS. The business’s revenue for the quarter was down 13.9% on a year-over-year basis. Analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insider Activity

In other news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $1.32 per share, with a total value of $891,000.00. Following the acquisition, the chief executive officer directly owned 214,676,448 shares of the company’s stock, valued at approximately $283,372,911.36. This represents a 0.32% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 49.69% of the stock is owned by company insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.